Method for forming a molded two-layer ocular implant
The present invention generally relates to local therapies for the eye and, more particularly, to shaped controlled-release ocular implant devices, including methods for making and using such devices, for delivery of therapeutic agents to the eye. A molded two-layer ocular implant comprises a therapeutic agent for treatment or prevention of a disorder of the eye. The implant comprises a polymer layer and a silicone adhesive layer with a therapeutic agent interspersed therein and joined to the polymer layer. This implant is for placement in the sub-Tenon's space of the eye and provides sustained release of the therapeutic agent during the treatment or prevention of the disorder of the eye.
1. A method for forming a molded two-layer ocular implant, the implant comprising a therapeutic agent for treatment of an ocular condition in a human or veterinary animal, the method comprising:
(a) dispensing a polymer into a curved depression on a mold body to form a polymer layer, said polymer layer having
(i) a curved external surface which is in contact with the bottom of the curved depression of the mold body wherein the curved external surface of the polymer layer generally conforms to the radius of curvature of the sub-Tenon's capsule of the eye, and
(ii) an exposed upper surface, wherein any excess polymer at the perimeter of the curved depression on the top surface of the mold body is trimmed;
(b) generating a curvature in the exposed upper surface of the polymer layer formed in (a) with a first impression body, said first impression body having a protrusion for generating said curvature, thereby forming a curved polymer layer interface surface;
(c) curing the polymer layer to completion prior to step (d), thereby providing a hardened curved polymer layer interface surface;
(d) dispensing a degassed silicone adhesive comprising the therapeutic agent dispersed therein onto the hardened curved polymer layer interface surface thereby providing a silicone drug layer with an exposed surface, and optionally degassing the silicone drug layer while in the mold body;
(e) generating a curvature in the exposed surface of the silicone drug layer comprising
(i′) contacting said silicone drug layer with a second impression body, said second impression body having a protrusion for generating said curvature and where the fitting of the second impression body places the perimeter of the second impression body substantially centrally within the perimeter of the depression by the first impression body, and
(ii′) optionally trimming any excess silicone drug polymer on the mold body, thereby forming a curved eye-contacting surface in the silicone drug layer, wherein the curved eye-contacting surface of the silicone drug layer generally conforms to the radius of curvature of the sclera of the eye; and
(f) curing the silicone drug layer formed in steps (d)-(e) thereby forming the molded two-layer ocular implant, wherein the polymer layer of the molded two-layer ocular implant extends circumferentially beyond the silicone drug layer of the molded two-layer ocular implant such that the surface of the circumferential extension of the polymer layer is capable of making contact with the sclera of the eye.
2. The method of claim 1 wherein the implant is circular or oval-shaped.
3. The method of claim 1 wherein the polymer layer is resistant to diffusion of the therapeutic agent from the silicone layer.
4. The method of claim 1 wherein the polymer layer is substantially impermeable to diffusion of the therapeutic agent from the silicone layer.
5. The method of claim 1 wherein the polymer layer and the silicone drug layer are each about 1 mm thick.
6. The method of claim 1 wherein the radius of curvature of the curved eye-contacting surface of the silicone layer ranges from between about 5 mm to about 6 mm.
7. The method of claim 1 wherein the resulting molded implant is circular with a diameter ranging between about 1 mm and 8 mm.
8. The method of claim 1 , comprising the step of mixing an agent that blocks lymphatic absorption with the polymer, wherein said mixing occurs prior to step (a).
9. The method of claim 8 wherein the polymer layer includes an agent that blocks lymphatic absorption of the therapeutic agent.